UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Histiocytose cutanée acquise régressive non langerhansienne de l'enfant

Annales de dermatologie et de vénéréologie, 1997-02, Vol.124 (2), p.167-170

1997

Volltextzugriff (PDF)

Important Considerations in Groupwork with Cancer Patients

Social work with groups (New York. 1978), 1990-09, Vol.13 (2), p.69-81

Daste, Barry M.

1990

Volltextzugriff (PDF)

Alternate considerations in the treatment of cholinesterase-inhibitor insecticide poisoning

Critical care nurse, 1985-05, Vol.5 (3), p.53-58

1985

Volltextzugriff (PDF)

Creative Short Term Group Therapy in a Managed Care Environment

Groupwork, 1995-01, Vol.8 (3), p.302-312

Daste, Barry M

1995

Volltextzugriff (PDF)

Important considerations in groupwork with cancer patients

Social work with groups (New York. 1978), 1990-01, Vol.13 (1990), p.69-81

Daste, B M

1990

Volltextzugriff (PDF)

Designing cancer groups for maximum effectiveness

Groupwork, 1989-01, Vol.2 (1989), p.58-69

Daste, B M

1989

Volltextzugriff (PDF)

Acquired regressive cutaneous non-Langerhans-cell histiocytosis in an infant

Annales de dermatologie et de vénéréologie, 1997, Vol.124 (2), p.167-170

1997

Volltextzugriff (PDF)

Duodenal Fasciola hepatica distomatosis

Maroc médical, 1953-06, Vol.32 (337), p.614

1953

Volltextzugriff (PDF)

Group Therapy for Medically Ill patients Edited by James L. Spira. New York: Guilford Press, 1997. 325 pp. $39.95 hardback, ISBN 1-57230-168-6

Health & Social Work, 1997, Vol.22 (4), p.313-313

Daste, B. M.

1997

Volltextzugriff (PDF)

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Annals of oncology, 2020-07, Vol.31 (7), p.942-950

2020

Volltextzugriff (PDF)

Institutionalized Aggressives in Louisiana

International journal of offender therapy and comparative criminology, 1973-01, Vol.17 (3), p.285-289

Daste, Barry M.

1973

Volltextzugriff (PDF)

853MO Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial

Annals of oncology, 2024-09, Vol.35, p.S615-S616

2024

Volltextzugriff (PDF)

Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors

Cancer Immunology, Immunotherapy, 2022-11, Vol.71 (11), p.2609-2618

2022

Volltextzugriff (PDF)

Development of a new patient‐reported outcome measure to assess activities and participation in people with systemic sclerosis: the Cochin 17‐item Scleroderma Functional scale

British journal of dermatology (1951), 2020-10, Vol.183 (4), p.710-718

2020

Volltextzugriff (PDF)

Stigma Reduction and the Corrections–Oriented Worker

Social casework, 1973-07, Vol.54 (7), p.418-423

1973

Volltextzugriff (PDF)

362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)

Annals of oncology, 2023-11, Vol.34, p.S1610-S1611

2023

Volltextzugriff (PDF)

909P Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial

Annals of oncology, 2024-09, Vol.35, p.S641-S641

2024

Volltextzugriff (PDF)

SAT0540 ONE-YEAR OUTCOMES AFTER RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FROM CHECKPOINT INHIBITORS

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.1227-1227

2020

Volltextzugriff (PDF)

Multiple-Influence Paradigms in Illness

Social casework, 1975-11, Vol.56 (9), p.531-537

1975

Volltextzugriff (PDF)

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study

Rheumatic & musculoskeletal diseases open, 2023-11, Vol.9 (4), p.e003795

2023

Volltextzugriff (PDF)

855MO Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)

Annals of oncology, 2023-10, Vol.34, p.S557-S557

2023

Volltextzugriff (PDF)

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort

Annals of oncology, 2018-10, Vol.29, p.viii373-viii373

2018

Volltextzugriff (PDF)

Management of Immune Checkpoint Inhibitor Toxicities

Cancer management and research, 2020, Vol.12, p.9139-9158

2020

Volltextzugriff (PDF)

916P Impact of sarcopenia (S) on efficacy and toxicity of nivolumab (N) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study

Annals of oncology, 2021-09, Vol.32, p.S809-S810

2021

Volltextzugriff (PDF)

1048OM7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(64)
Berichte
(1)
Reviews
(1)

Sprache

Englisch
(48)
Französisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Histiocytose cutanée acquise régressive non langerhansienne de l'enfant

Important Considerations in Groupwork with Cancer Patients

Alternate considerations in the treatment of cholinesterase-inhibitor insecticide poisoning

Creative Short Term Group Therapy in a Managed Care Environment

Important considerations in groupwork with cancer patients

Designing cancer groups for maximum effectiveness

Acquired regressive cutaneous non-Langerhans-cell histiocytosis in an infant

Duodenal Fasciola hepatica distomatosis

Group Therapy for Medically Ill patients Edited by James L. Spira. New York: Guilford Press, 1997. 325 pp. $39.95 hardback, ISBN 1-57230-168-6

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Institutionalized Aggressives in Louisiana

853MO Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial

Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors

Development of a new patient‐reported outcome measure to assess activities and participation in people with systemic sclerosis: the Cochin 17‐item Scleroderma Functional scale

Stigma Reduction and the Corrections–Oriented Worker

362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)

909P Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial

SAT0540 ONE-YEAR OUTCOMES AFTER RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FROM CHECKPOINT INHIBITORS

Multiple-Influence Paradigms in Illness

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study

855MO Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort

Management of Immune Checkpoint Inhibitor Toxicities

916P Impact of sarcopenia (S) on efficacy and toxicity of nivolumab (N) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study

1048OM7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort

Suchergebnisse filtern